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Introduction {#sec1}
============

Iron, an essential metal for life, is a crucial regulator of innate immunity through macrophage function. Considering its vast pleiotropic roles in cellular homeostasis and its preferential enrichment in proteins belonging to mitochondria and the endoplasmic reticulum (ER; [@bib4]), iron has a master regulatory role in macrophage metabolism and its crosstalk with immune plasticity. Iron-dependent immunometabolism in macrophages occurs at multiple levels. Iron could be integrated into heme or iron-sulfur (Fe-S) clusters, which in turn are incorporated into specific protein families (hemoproteins and Fe-S cluster proteins) that orchestrate metabolic and immunological functions in macrophages ([@bib1], [@bib17], [@bib63], [@bib76]). Furthermore, in its non-heme, Fe^2+^ form, iron can govern the activity of enzymes such as α-ketoglutarate (αKG)-dependent dioxygenases upstream of oxygen sensing and epigenetic modifications ([@bib40], [@bib47]) or lipoxygenases responsible for generating bioactive lipid mediators ([@bib23]). Besides its role in promoting immune activation in macrophages, iron is crucial in regulating the fundamental properties of eukaryotic cells such as DNA replication ([@bib49]) and repair ([@bib60]), and there is evidence of macrophage iron levels affecting the proliferation of stromal cells ([@bib58]).

Macrophages show a sophisticated fine-tuning of intracellular iron availability during bacterial and fungal pathogenicity, a concept recently referred to as innate nutritional immunity ([@bib5], [@bib46], [@bib50]). Iron homeostasis affecting macrophage plasticity was also studied in the context of sterile inflammation and cancer. It has been reported that iron overloading in macrophages occurs in human chronic venous leg ulcers and cause an unrestrained pro-inflammatory M1-like phenotype ([@bib62]). Likewise, increased intracellular iron polarizes the macrophages toward a detrimental pro-inflammatory state in the injured spinal cord ([@bib36]), and iron-positive microglia and macrophages in chronic active multiple sclerosis lesions are thought to be a source of inflammation that correlates with tissue damage and disease severity ([@bib20]). In keeping with these findings, in a mouse model of sickle disease, hemolysis and macrophage heme-iron accumulation trigger a proinflammatory phenoytpe in hepatic macrophages ([@bib78]). In cancer, iron-loaded tumor-associated macrophages adopt a pro-inflammatory phenotype that can directly kill tumor cells ([@bib11]), and the usage of iron oxide nanoparticles is an attractive avenue in cancer immunotherapy through the modulation of macrophage activity ([@bib22], [@bib84]). In summary, the findings from all of the above-mentioned studies converge toward a macrophage polarization profile resulting from prolonged exposure to iron in the tissue microenvironment, correlating with a pro-inflammatory (M1-like) phenotype. Although this phenotype associates with tissue damage during inflammatory disease ([@bib36], [@bib62], [@bib78]), it has been reported to be beneficial in cancer ([@bib11], [@bib84]).

Studies aiming to experimentally induce acute changes in cellular iron metabolism during inflammation are scarce. Reducing mitochondrial iron in the heart protects mice against ischemia-reperfusion injury ([@bib10]). In human cell lines, acute iron deprivation results in profound mitochondria-driven metabolic changes, such as marked citrate accumulation followed by lipid synthesis and decreases the protein levels of several Fe-S cluster biogenesis proteins ([@bib12], [@bib76]). These studies suggest that acute manipulation of macrophage iron pools could reprogram its metabolism in the inflammatory microenvironment. However, a comprehensive study on the effects of iron manipulation in macrophage metabolism is lacking. Here, we induced acute iron chelation in primary human macrophages and measured their metabolic and transcriptional responses by stable isotope tracing and RNA sequencing (RNA-seq). We show that iron deficiency triggers hypoxia-inducible factor (HIF-1)-glycolysis and interferon (IFN) transcriptional responses, while there is a generalized downregulation of cell cycle-mitosis and oxidative phosphorylation (OXPHOS) pathways. We identify ATF4 as an iron-responsive transcription factor in human macrophages and show iron-dependent modulation of the expression of some of its known targets. These major responses were rescued with short exposure to FeCl~3~ following iron chelation. Metabolically, glucose-derived citrate accumulates markedly and induces intracellular lipid droplet formation, and to a lesser extent itaconate synthesis, when macrophages lack iron. This is associated with the inhibition of the tricarboxylic acid (TCA) cycle, partly due to the downregulation of succinate dehydrogenase complex iron sulfur subunit B (SDHB) and the loss of mitochondrial aconitase activity. Consequently, OXPHOS is abolished and glycolysis is enhanced as a result of iron deprivation in human macrophages. Lipopolysaccharide (LPS) polarization of iron-deprived human macrophages shows that while the itaconate:succinate ratio is increased, the pro-inflammatory cytokines interleukin-1β (IL-1β) and tumor necrosis factor α (TNF-α) are reduced. This suggests that iron chelation restrains LPS polarization, which is further supported by RNA-seq analysis showing the induction of the transforming growth factor β (TGF-β) pathway in LPS-stimulated iron-deprived macrophages. *In vivo*, acute iron deprivation reduces the severity of macrophage-dependent crescentic glomerulonephritis by limiting glomerular cell proliferation and induces significant lipid droplet accumulation in the renal cortex.

Our study shows that acute iron deprivation results in a profound metabolic remodeling, promoting an atypical Warburg effect with anti-inflammatory properties in human macrophages. We confirm the beneficial effects of iron deprivation *in vivo* and propose macrophage iron manipulation as a potential therapeutic approach targeting immunometabolism in these cells.

Results {#sec2}
=======

Acute Iron Chelation Causes an Atypical Warburg Transcriptome in Human Macrophages {#sec2.1}
----------------------------------------------------------------------------------

In mitochondria, the TCA cycle activity, respiration complexes, and heme biosynthesis are dependent on iron availability and Fe-S cluster biogenesis. Iron chelators with low membrane permeability such as deferoxamine cannot access the mitochondria, whereas deferiprone (DEF; 3-hydroxy-1,2-dimethylpyridin-4-one) is membrane permeable and can enter mitochondria ([@bib64]). RNA-seq of human macrophages treated with DEF showed a clear transcriptional response. As previously shown for iron chelation by chemical hypoxia mimetics ([@bib3], [@bib56]), we confirmed a glycolysis-HIF-P53 signature among the significantly upregulated gene families ([Figures 1](#fig1){ref-type="fig"}A and [S1](#mmc1){ref-type="supplementary-material"}). These cells also show an induction of IFN signaling, while cell division-mitosis and OXPHOS were downregulated ([Figure 1](#fig1){ref-type="fig"}A). Given the previously established role of iron chelation in pseudohypoxia ([@bib56]) and cell division-mitosis ([@bib38]), these results suggested iron-dependent transcriptomic changes in human macrophages. To further confirm that the transcriptional effects were due to the iron-chelation properties of DEF, human macrophages were treated with DEF, after which FeCl~3~ was added for 8 h. qRT-PCR for the most significant genes belonging to glycolysis-HIF, OXPHOS, and cell division-mitosis showed significant rescue of the DEF effect with iron supplementation in some of the transcripts ([Figures 1](#fig1){ref-type="fig"}B and 1C). These results suggested that the major transcriptomics changes obtained with DEF treatment are due to iron deprivation in human macrophages. Since the results show that acute iron deprivation is associated with metabolic changes, we next examined how DEF compares to the well-established lipopolysaccharide (LPS)-mediated transcriptome characterized by increased glycolysis and attenuated OXPHOS in macrophages ([@bib33], [@bib43]). Comparative RNA-seq analysis between LPS and DEF-treated human macrophages showed that iron deprivation downregulated activating transcription factor 4 (ATF4)-mediated gene activation ([Figure S1](#mmc1){ref-type="supplementary-material"}). This was not present in LPS-treated cells, which showed the upregulation of well-established Toll-like receptor, Janus kinase/signal transducer and activator of transcription (JAK/STAT), and nucleotide-binding oligomerization domain-like (NOD-like) receptor signaling pathways ([Figure S1](#mmc1){ref-type="supplementary-material"}). We subsequently confirmed that ATF4 protein levels and the expression of some of its known target genes are dependent on acute changes in iron ([Figures 1](#fig1){ref-type="fig"}D and [S1](#mmc1){ref-type="supplementary-material"}). To confirm the role of ATF4 in a more clinical setting, we examined the acute effects of intravenous iron administration in patients with stable, non-immune chronic kidney disease (CKD), who were receiving iron therapy as part of their routine clinical care. Peripheral blood mononuclear cells (PBMCs) were collected before and 120 min following intravenous iron (Ferinject 1--1.5 g) infusion, and ATF4 protein levels showed a clear increase following iron transfusion in all of the patients ([Figure 1](#fig1){ref-type="fig"}E), confirming its iron-mediated rapid induction.Figure 1Acute Iron Deprivation Causes an Atypical Warburg Transcriptome and Mediates an ATF4-Driven Transcriptional Response in Human Macrophages(A) Gene set enrichment analysis (GSEA) in upregulated and downregulated transcripts between control (basal) and DEF-treated human macrophages (500 μM, 24 h), measured by RNA-seq (n = 3 donors; Fc \> 1.5; P~adj~ \< 0.01).(B) Volcano plot from RNA-seq highlighting genes belonging to glycolysis-HIF, cell division, and OXPHOS pathways.(C) qRT-PCR for main glycolysis-HIF, cell division, and OXPHOS genes (color-coded) in iron-deprived (DEF, 500 μM, 24 h) and rescued human macrophages with short exposure (8 h) to 200 μM ferric chloride (DEF + FeCl~3~); n = 4--9 donors/group.(D) ATF4 western blotting in iron-deprived (DEF) and rescued (DEF + FeCl~3~) human macrophages from three donors.(E) ATF4 western blotting before and after 2 h of intravenous iron transfusion (Ferinject 1--1.5 g) in 3 CKD patients' PBMCs (see [Method Details](#sec4.4){ref-type="sec"} and [Table S1](#mmc1){ref-type="supplementary-material"} for patient information). ^∗^p \< 0.05, ^∗∗^p \< 0.01, and ^∗∗∗^p \< 0.001 by ANOVA followed by Tukey's multiple comparisons test. *P*~adj~, adjusted p value; Fc, fold change. Error bars represent SEM.See also [Figures S1](#mmc1){ref-type="supplementary-material"} and [S2](#mmc1){ref-type="supplementary-material"}.

Since metabolic consequences of acute iron deprivation and defective Fe-S cluster assembly are similar in human cell lines ([@bib12]), we next tested an alternative, drug-free method of acute iron deprivation and replenishment in human macrophages. RNA interference for *ISCU*, a primary Fe-S biogenesis scaffold protein known to have a master regulatory role in cellular iron levels, showed comparable transcriptomic responses to DEF (upregulation of glycolysis-HIF-IFN and downregulation of cell-cycle pathways) and the addition of FeCl~3~ rescued the majority of the effects ([Figure S2](#mmc1){ref-type="supplementary-material"}). Likewise, *ISCU* knockdown resulted in ATF4 downregulation, which was rescued with the addition of FeCl~3~ in human macrophages ([Figure S2](#mmc1){ref-type="supplementary-material"}).

Acute Iron Chelation Causes a Metabolic Switch in Human Macrophages {#sec2.2}
-------------------------------------------------------------------

Iron deprivation resulted in increased glycolysis-HIF, decreased OXPHOS transcriptome pathways in human macrophages ([Figure 1](#fig1){ref-type="fig"}), indicative of a dysregulation of mitochondrial function. This was further supported by the suppression of the gene expression of respiratory chain enzymes containing Fe-S clusters, *NDUFS6* and *SDHB* (also known as the Fe-S subunit of complex II; [Figure 1](#fig1){ref-type="fig"}C). Since SDHB links the TCA cycle to OXPHOS ([@bib45]), we next investigated the iron-dependent control of its protein levels. SDHB protein levels were found to be controlled by intracellular iron levels, as iron replenishment following deprivation brought the levels of this protein back to its basal state ([Figure 2](#fig2){ref-type="fig"}A). As expected, iron-dependent mitochondrial aconitase activity was inhibited by DEF ([Figure 2](#fig2){ref-type="fig"}B). Iron replenishment partly restored mitochondrial aconitase activity and induced cytoplasmic aconitase activity in human macrophages ([Figure 2](#fig2){ref-type="fig"}B). In agreement with SDHB downregulation and loss of aconitase activity, OXPHOS was nearly totally inhibited following iron deprivation in human macrophages ([Figure 2](#fig2){ref-type="fig"}C). To measure the glycolytic rate, we incubated cells with uniformly labeled \[U\]-^13^C-glucose and assessed the production of glucose-derived lactate using liquid chromatography-mass spectrometry (LC-MS). In line with the transcriptional changes, we found a significant increase in the secreted glucose-derived lactate (M+3) with no change in the consumption of glucose levels following DEF treatment ([Figures 2](#fig2){ref-type="fig"}D and 2E). Consistently, extracellular acidification rate (ECAR) was enhanced in DEF-treated human macrophages ([Figure 2](#fig2){ref-type="fig"}F). These results functionally validated the transcriptional analyses and confirmed that DEF elicits a metabolic switch whereby glycolysis is enhanced and mitochondrial function is suppressed.Figure 2Acute Iron Deprivation Abolishes Oxidative Phosphorylation and Increases Aerobic Glycolytic Flux in Human Macrophages(A) SDHB western blotting in iron-deprived (DEF) and rescued (DEF + FeCl~3~) human macrophages from three donors. DEF (24 h, 500 μM); FeCl~3~ (8 h, 200 μM).(B) Aconitase activity gel in iron-deprived (DEF) and rescued (DEF + FeCl~3~) human macrophages from two donors. m-aconitase, mitochondrial; c-aconitase, cytosolic.(C) Oxygen consumption rate (OCR) measurement by extracellular flux analysis in control and DEF-treated human macrophages. Basal and maximal respiration and ATP production are shown at right. R/A, rotenone/antimycin; 2-DG, 2-deoxyglucose; DEF (24 h, 500 μM); n = 4 donors.(D) Intracellular and extracellular lactate (glucose-derived adduct shown at left) isotopologue quantification by LC-MS in iron-deprived (DEF, 500 μM, 24 h) and rescued human macrophages with short exposure to 200 μM ferric chloride (DEF + FeCl~3~); n = 6 donors.(E) Extracellular glucose M+6 by LC-MS; n = 6 donors.(F) Extracellular acidification rate (ECAR) measured by extracellular flux analysis. R/A, rotenone/antimycin; 2-DG, 2-deoxyglucose, DEF (24 h, 500 μM); n = 4 donors.Significance tested by t test (C, D, and F) and ANOVA followed by Dunnett's multiple comparisons test (E). ns, non-significant compared to Ctrl. ^∗∗^p \< 0.01 and ^∗∗∗^p \< 0.001. Error bars represent SEM.

A Citrate Checkpoint Characterizes Acute Iron Deprivation in Human Macrophages {#sec2.3}
------------------------------------------------------------------------------

To gain more insights into metabolic pathways affected by acute iron deprivation and replenishment, we incubated untreated, iron-deprived, and iron-repleted human macrophages with the tracer \[U\]-^13^C-glucose and assessed its fate in the TCA cycle ([Figure 3](#fig3){ref-type="fig"}A). Iron deprivation and replenishment was well tolerated in human macrophages ([Figure S3](#mmc1){ref-type="supplementary-material"}). We observed a striking increase in citrate levels upon DEF treatment ([Figure 3](#fig3){ref-type="fig"}B). The isotopologue distribution analysis ([Figure 3](#fig3){ref-type="fig"}A) revealed that the increased intracellular citrate pools were predominantly glucose derived ([Figures 3](#fig3){ref-type="fig"}B and [S3](#mmc1){ref-type="supplementary-material"}). Glucose-derived citrate was partly converted to aconitate and itaconate ([Figures 3](#fig3){ref-type="fig"}A, 3B, and [S3](#mmc1){ref-type="supplementary-material"}), but in relatively modest quantities, which is consistent with the inhibition of the iron-dependent mitochondrial aconitase activity ([Figure 2](#fig2){ref-type="fig"}B). Metabolites derived from the TCA cycle activity, such as M+2 glutamate and glutathione (GSH), were decreased, while M+2 malate remained unchanged ([Figures S3](#mmc1){ref-type="supplementary-material"} and [S4](#mmc1){ref-type="supplementary-material"}). This was also the case for the extracellular glutamate, reflected by a reduction in M+2 glutamate ([Figure S4](#mmc1){ref-type="supplementary-material"}). These results suggested an inhibition of the TCA cycle between aconitate and αKG. Furthermore, since nitric oxide synthases (NOSs) are heme-dependent enzymes responsible for nitric oxide generation from the oxidation of [l]{.smallcaps}-arginine to citrulline ([@bib48]), iron chelation showed an effect on cellular and extracellular arginine and citrulline pools in human macrophages ([Figure S4](#mmc1){ref-type="supplementary-material"}).Figure 3A Citrate Checkpoint Characterizes Iron-Deprived Human Macrophages(A) Diagram of uniformly labeled \[U\]-^13^C-glucose catabolism, highlighting the TCA cycle metabolites and their expected glucose-derived ^13^C atoms.(B) Stacked isotopologues measured by LC-MS shown for citrate, aconitate, itaconate, and glutamate in iron-deprived (DEF, 500 μM, 24 h) and rescued human macrophages with short exposure (8 h) to 200 μM ferric chloride (DEF + FeCl~3~); n = 6 donors.(C) Vehicle, DEF-treated, or concomitant DEF and FeCl~3~-treated human macrophages stained for oil red O. The results are representative of n = 4 donors.(D) Summary of the TCA cycle changes due to iron deprivation in human macrophages. Citrate accumulation resulting from aconitase (ACO) inhibition and SDHB downregulation and the fate of citrate-derived metabolites are illustrated. Dashed circle represents inhibited TCA cycle activity. αKG, α-ketoglutarate.Scale bars, 40 μm.See also [Figures S3](#mmc1){ref-type="supplementary-material"} and [S4](#mmc1){ref-type="supplementary-material"}.

Citrate is an important checkpoint metabolite in immunometabolism, critically positioned at the crosstalk between glucose catabolism, fatty acid synthesis, and oxidation ([@bib74], [@bib82]). We next hypothesized that marked citrate accumulation following acute iron deprivation could result in lipid droplet accumulation. In line with this hypothesis, DEF-treated human macrophages exhibited a striking increase in lipid droplet accumulation, which was diminished by co-incubation of DEF with FeCl~3~ ([Figure 3](#fig3){ref-type="fig"}C). Lipid accumulation was similarly reduced when the fatty acid synthase (FASN) inhibitor cerulenin was used together with DEF treatment ([Figure S4](#mmc1){ref-type="supplementary-material"}), suggesting that *de novo* synthesis is engaged in iron-depleted macrophages.

In summary, the metabolic reprogramming due to iron deprivation results in marked citrate accumulation, which partly translates into aconitate and itaconate production together with lipid droplet accumulation ([Figure 3](#fig3){ref-type="fig"}D). Oxidative phosphorylation is inhibited and αKG-derived metabolites show a decrease, suggesting overall diminished activity of the TCA cycle. This causes a compensatory increase in aerobic glycolysis with the subsequent production and secretion of lactate ([Figure 3](#fig3){ref-type="fig"}D).

Acute Iron Deprivation and Pro-inflammatory Macrophage Polarization {#sec2.4}
-------------------------------------------------------------------

To find out how this specific iron-deficient macrophage phenotype undergoes the classical pro-inflammatory activation, we polarized DEF-treated human macrophages with LPS stimulation and measured IL-1β and TNF-α production. The results showed a reduction in secreted factors in iron-chelated macrophages ([Figure 4](#fig4){ref-type="fig"}A). We then performed a time course analysis of LPS treatment in DEF-treated macrophages and measured 88 metabolites by LC-MS, including citrate, aconitate, itaconate, and succinate ([Figure 5](#fig5){ref-type="fig"}). We first confirmed the truncated TCA cycle in LPS-stimulated iron-deprived macrophages with increased citrate (and citrate:succinate ratio) and aconitate and decreased αKG and glutamate levels ([Figures 4](#fig4){ref-type="fig"}B, 4C, and [S5](#mmc1){ref-type="supplementary-material"}). Itaconate production is further augmented in DEF-treated human macrophages, and the itaconate:succinate ratio was increased at 24 h ([Figures 4](#fig4){ref-type="fig"}B and 4C), which is indicative of overall anti-inflammatory metabolic switching ([@bib45]). *IRG1* mRNA levels did not show an apparent DEF effect, suggesting that the effects of iron deprivation on itaconate levels are likely to be mediated by changes in metabolic fluxes, rather than by the transcriptional regulation of *IRG1* ([Figure S5](#mmc1){ref-type="supplementary-material"}). Comparative RNA-seq analysis between LPS and LPS + DEF-treated macrophages during early activation (3 h) confirmed the results obtained with Ctrl versus DEF comparison (i.e., increased glycolysis, IFN-γ signaling, decreased OXPHOS, and DNA replication; [Figure S5](#mmc1){ref-type="supplementary-material"}). Iron-depleted macrophages stimulated with LPS showed upregulation of the TGF-β signaling pathway, which is associated with increases in *TGFB1*, *VEGFA*, *CTGF*, *CXCL12*, *IL10*, and *IL1RN* expression levels ([Figure S5](#mmc1){ref-type="supplementary-material"}). Considering the anti-inflammatory role of itaconate ([@bib7], [@bib44]), these results suggest that acute iron chelation limits the classical macrophage polarization by increasing the itaconate:succinate ratio, decreasing secreted IL-1β, and TNF-α, and promoting the early induction of the TGF-β signaling pathway.Figure 4Acute Iron Chelation Limits the Pro-inflammatory Macrophage Polarization(A) IL-1β and TNF-α production in iron-deprived human macrophages (500 μM, 24 h), following LPS treatment (100 ng/mL, 24 h; LPS + DEF); n = 7 donors.(B) LC-MS for citrate, itaconate, and succinate in basal and DEF-treated macrophages (500 μM, 24 h) throughout an LPS (100 ng/mL) time course; n = 4 donors.(C) Itaconate:succinate and citrate:succinate ratios at 24 h; n = 4 donors.Significance tested by ANOVA followed by Tukey's multiple comparisons test (A) and t test (B and C). ^∗^p \< 0.05, ^∗∗^p \< 0.01, and ^∗∗∗^p \< 0.001. Error bars represent SEM.See also [Figure S5](#mmc1){ref-type="supplementary-material"}.Figure 5Acute Iron Chelation and Time Course Metabolomics in LPS-Stimulated Human MacrophagesHeatmap for LC-MS analysis of 88 metabolites in basal (Ctrl), LPS treated (1, 3, 8, and 24 h) and LPS + DEF-treated human macrophages; DEF treatment is 500 μM, 24 h; n = 4 donors.

Acute Iron Deprivation Is Preventive in Glomerulonephritis and Induces *De Novo* Lipogenesis {#sec2.5}
--------------------------------------------------------------------------------------------

To investigate the pathophysiological significance of acute iron deprivation in a macrophage-dependent inflammatory disease model, crescentic glomerulonephritis was induced in the Wistar Kyoto rats treated either with vehicle or DEF ([Figure 6](#fig6){ref-type="fig"}A). Oral DEF treatment markedly lowered the levels of proteinuria during the entire disease course ([Figure 6](#fig6){ref-type="fig"}B) and ameliorated glomerular morphology ([Figure 6](#fig6){ref-type="fig"}C). The glomeruli of the DEF-treated group had a substantially reduced fibrin score and crescent formation as well as decreased glomerular size ([Figure 6](#fig6){ref-type="fig"}D). Since the WKY nephrotoxic nephritis (NTN) model depends on the infiltration and activation of monocytes and macrophages ([@bib8]), we performed ED-1 (rat CD68) staining and showed that DEF significantly decreased the number of monocytes and macrophages in the glomeruli ([Figure S6](#mmc1){ref-type="supplementary-material"}). We then checked whether the lipid accumulation as a result of iron deprivation was conserved *in vivo* and found increased oil red O staining in DEF-treated rat glomeruli and renal cortex following NTN ([Figure 6](#fig6){ref-type="fig"}E), suggesting that the citrate-derived *de novo* fatty acid synthesis occurs during acute iron deprivation in experimental crescentic glomerulonephritis. Furthermore, since iron deprivation caused a downregulation of cell cycle-mitosis pathways measured by RNA-seq ([Figure 1](#fig1){ref-type="fig"}A), we measured intraglomerular cell proliferation and found decreased proliferating glomerular cell nuclear antigen (PCNA) in DEF-treated animals following the induction of NTN ([Figure 6](#fig6){ref-type="fig"}F).Figure 6Acute Iron Deprivation Protects against Crescentic Glomerulonephritis and Induces *De Novo* Lipid Accumulation(A) Experimental design.(B) Amount of urinary protein at different time points during the course of NTN; n=3 or 4 rats/group.(C) PAS staining showing representative glomerular morphology of the vehicle (left) and the DEF (right) groups.(D) Glomerular fibrin score, percentage of glomeruli with crescents, and glomerular size in vehicle and DEF-treated rats; n = 3 or 4 rats/group.(E) Nephritic glomeruli of vehicle- or DEF-treated rats showing oil red O^+^ glomerular and tubular cells in the DEF group.(F) PCNA staining showing proliferating cells in nephritic glomeruli; number of nuclear PCNA(+) cells in the glomeruli (bottom); n = 3 or 4 rats/group.(G) Experimental design for the therapeutic experiment.(H) Amount of urinary protein levels at different time points during the course of NTN; n = 4 or 5 rats/group.(I) PAS staining showing representative glomerular morphology of the vehicle (left) and DEF (right) groups.(J) Glomerular fibrin score, percentage of glomeruli with crescents, and glomerular size in vehicle- and DEF-treated rats; n = 4 or 5 rats/group.^∗^p \< 0.05, ^∗∗^p \< 0.01, and ^∗∗∗^p \< 0.001 by t test. Scale bars, 40 μm. Error bars represent SEM.See also [Figure S6](#mmc1){ref-type="supplementary-material"}.

To assess whether DEF has therapeutic effects after the onset of glomerulonephritis, rats were treated with or without DEF from day 4 following the induction of NTN, which corresponds to the onset of renal damage and proteinuria. The rats were then sacrificed on day 10, at the peak of glomerular inflammation ([Figure 6](#fig6){ref-type="fig"}G). Notably, the progression of proteinuria at day 10 was reversed in rats treated with DEF when compared to either the treated group on day 7 or their control counterparts at day 10 ([Figure 6](#fig6){ref-type="fig"}H). The glomerular morphology of DEF-treated rats at day 10 showed improved features when compared to vehicle-treated rats ([Figure 6](#fig6){ref-type="fig"}I), which was also accompanied by reduced fibrin score and crescent formation together with decreased glomerular size ([Figure 6](#fig6){ref-type="fig"}J). Monocyte/macrophage infiltration was significantly decreased by DEF ([Figure S6](#mmc1){ref-type="supplementary-material"}), and acute iron deprivation by DEF resulted in ameliorated renal function (i.e., reduced creatinine and blood urea nitrogen) associated with reduced intraglomerular cell proliferation ([Figure S6](#mmc1){ref-type="supplementary-material"}). DEF treatment did not alter erythropoiesis as hemoglobin levels were not significantly altered ([Figure S6](#mmc1){ref-type="supplementary-material"}). In addition to its therapeutic effects *in vivo*, DEF reduced superoxide production in the NTN-susceptible WKY rat bone marrow-derived macrophages (BMDMs) and its antioxidant properties were confirmed in a cell-free superoxide production system ([Figure S6](#mmc1){ref-type="supplementary-material"}). In summary, *in vivo* iron chelation in macrophage-dependent renal inflammation is accompanied by metabolic and transcriptomic changes (*de novo* lipid accumulation, anti-proliferative responses) that are conserved *in vitro* cultured human macrophages.

Discussion {#sec3}
==========

Iron serves as a prosthetic group for proteins orchestrating immunometabolic responses at multiple levels in macrophages. For instance, mammalian complex I hosts as many as eight Fe-S clusters ([@bib79]), allowing optimal electron transfer during OXPHOS and maintaining the balance between the generation of reactive oxygen species (ROS) and ATP production ([@bib43]). Furthermore, non-mitochondrial ROS production, an essential feature of macrophage-driven immune phagocytic responses, is partly mediated by NOX2 (CYBB), which uses heme-iron for superoxide generation ([@bib67]). In this study, we showed that iron deprivation caused an induction of glycolysis-HIF and a repression of OXPHOS pathways in human macrophages. Dendritic cells and macrophages, when stimulated with pro-inflammatory stimuli, decrease OXPHOS with a simultaneous upregulation of glycolysis and activity in the pentose phosphate pathway ([@bib35], [@bib43], [@bib71]). Although iron deprivation and pro-inflammatory M1-type macrophage stimulation share the same metabolic switch, the underlying mechanisms are likely to differ. The inhibition of OXPHOS is explained by nitric oxide-mediated nitrosylation of mitochondrial Fe-S clusters in LPS-stimulated murine macrophages ([@bib17], [@bib18]). Instead, iron deprivation directly affects the expression and protein levels of respiratory chain Fe-S enzymes such as *NDUFS6* and *SDHB*. It causes the loss of OXPHOS and ATP production, partly by reducing SDHB levels in conjunction with the inhibition of mitochondrial aconitase activity. The rapid increase in SDHB levels following iron replenishment suggests the existence of an iron-responsive element in *SDHB* mRNA, which was previously reported in *Drosophila* ([@bib34]). Furthermore, SDHB deletion was associated with reduced IL-1β and HIF-1α in LPS-stimulated macrophages ([@bib43]), although LPS stimulation itself was shown to diminish SDHB protein levels in RAW264.7 cells ([@bib76]). Considering the large-scale suppression of Fe-S cluster biogenesis proteins in response to TLR4 activation in murine cell lines ([@bib76]) and the previously described iron-sequestration phenotype in M1 human macrophages ([@bib57]), one could speculate that mitochondrial iron deprivation, M1 activation, and ISCU small interfering RNA (siRNA) or mutagenesis share in the common inhibition of OXPHOS and a concomitant increase in aerobic glycolysis in macrophages.

DEF is an orally active Food and Drug Administration (FDA)-approved iron chelator that preferentially binds to ferric iron (Fe^3+^) in a 3:1 configuration and is used as alternative or complementary to deferoxamine treatment in hemoglobinopathies characterized by iron overload ([@bib27]). DEF can enter the mitochondria and shuttle iron between subcellular compartments ([@bib64]). Because of its low affinity to iron, DEF is less likely to cause iron depletion, which we also confirmed by measuring DEF-treated mitochondrial and cytosolic iron in human macrophages (data not shown). The ability of DEF to chelate mitochondrial iron and to make it available for other cellular compartments ([@bib31]) has therapeutic benefit for disorders such as Friedreich ataxia characterized by altered mitochondrial Fe-S cluster biogenesis ([@bib52]). More generally, mitochondrial iron handling is central to regulating cellular and systemic homeostasis ([@bib55]). In this context, the distinct properties of DEF make this drug ideal for studying the metabolic consequences arising from mitochondrial iron imbalances rather than measuring the indirect effects of extracellular iron chelation obtained by using deferoxamine. Iron imbalances between mitochondria and cytosol can have broad pathological consequences in cancer through altered immunometabolism ([@bib39]), and the genetic deficiencies of mitochondria-related genes (*FH*, *PINK1*) are likely to trigger dysregulation of the mitochondria-cytosol iron balance, which is associated with the Warburg effect and HIF signature in cancer ([@bib39], [@bib75], [@bib77]). We observed a macrophage pseudohypoxia transcriptome (i.e., HIF response in the presence of oxygen; [@bib61], [@bib71]) with DEF treatment, which was previously described in LPS-stimulated macrophages ([@bib71]). One limitation of our study is that the use of FeCl~3~ for iron replenishment *in vitro* does not mimic exposure to heme-iron, which occurs *in vivo* through the phagocytosis of red blood cells by macrophages due to hemorrhage, as reported in spinal cord injury ([@bib36]). In hemolytic diseases, which are characterized by the enhanced release of hemoglobin and heme into the circulation, heme-iron loading of reticulo-endothelial system macrophages changes their activation ([@bib78]). Nonetheless, macrophages can also be exposed to non-heme iron released from dying cells, and it should also be noted that the pro-oxidant properties FeCl~3~ may exacerbate the oxidative stress and trigger the ATF4 response.

One major transcriptional response that was specific to DEF treatment was ATF4 downregulation. Given the induction of this transcription factor in oxidative and ER stress responses ([@bib2]) and during heme-dependent erythroid differentiation ([@bib68]), this result confirms the antioxidant properties of DEF and its effect on superoxide neutralization. Furthermore, ATF4 reprograms CD4^+^ T cell metabolism and immune response ([@bib83]), and it is therefore conceivable that it has a similar role in human macrophages, especially given its effect on glutathione levels ([@bib83]). Another distinct feature of acute iron deprivation was its modest itaconate production when compared to LPS-stimulated human macrophages, which produce large amounts of this anti-inflammatory metabolite ([@bib44], [@bib53]). The limited itaconate production with iron deprivation could come from the type 1 interferon response affecting IRG1 gene expression ([@bib44]). Considering the anti-inflammatory ([@bib37], [@bib44]) and pro-tumorigenic ([@bib80]) effects of itaconate, it may contribute to the broadly anti-inflammatory macrophage phenotype we observe following iron deprivation. LPS stimulation augments itaconate production in iron-deprived macrophages and increases the itaconate:succinate ratio, while decreasing IL-1β and TNF-α secretion and promoting the TGF-β signaling pathway. These results indicate that acute iron chelation limits classic LPS polarization partly through the immunomodulatory properties of itaconate. A recent addition to the latter is the inhibitory effects of itaconate during immune tolerance ([@bib15]). Furthermore, itaconate is bactericidal, which is in line with the previously established antibacterial properties of iron chelators ([@bib72]).

Acute iron deprivation in human macrophages resulted in a robust citrate accumulation, which could be primarily attributed to aconitase inhibition. Mitochondrial and cytosolic aconitases catalyze the interconversion of citrate and isocitrate, and their activities are affected by cellular iron and oxidative levels and the activity of Fe-S biogenesis ([@bib74]). Citrate can be transported across the inner mitochondrial membrane via the tricarboxylate carrier, and once in the cytosol, it is the substrate of ATP-citrate lyase, which generates acetyl-coenzyme A (CoA), the building block of cholesterol and the fatty acids. *De novo* fatty acid synthesis is the hallmark of LPS-stimulated dendritic cells ([@bib19]) and macrophages ([@bib9]). Fatty acid oxidation has been associated with pro-inflammatory macrophage activation ([@bib24], [@bib25]), which highlights the complexity of lipid metabolism and the possible master-regulatory role of citrate in fine-tuning context-dependent macrophage responses. Here, we found that macrophages accumulate lipid droplets as a result of iron deprivation. In contrast with what was observed with TNF/IFN stimulation ([@bib30]), the marked citrate accumulation was not associated with a pro-inflammatory signal, suggesting that citrate pools are preferentially used for lipogenesis, causing steatosis in macrophages and nephritic kidneys. Citrate and iron metabolism are intimately linked as citrate can chelate divalent cations such as Fe^2+^ and is proposed to be one of the carriers of non-transferrin-bound iron ([@bib21]). It can also inhibit succinate oxidation ([@bib28]). Systemically, elevated citrate levels have been linked to increased hepcidin mRNA expression in primary hepatocytes and *in vivo* ([@bib13]), suggesting the existence of a citrate-iron regulatory feedback loop in macrophages. Citrate has also been linked to IFN-γ production through the acetylation of glyceraldehyde 3-phosphate dehydrogenase (GAPDH) in T cells ([@bib6]), a mechanism that could explain enhanced IFN response in iron-deprived human macrophages.

Studies on macrophage polarization following the manipulation of intracellular iron levels by different means has resulted in contrasting results, presumably because of the different model systems and the possible existence of a critical concentration of intracellular iron that likely drives the polarization ([@bib58]). While treatment with hepcidin resulted in the attenuation of the inflammatory response in LPS-treated macrophages ([@bib14]), dietary iron restriction rendered spleen macrophages pro-inflammatory following sublethal LPS injection in mice ([@bib51]). No obvious changes in BMDM polarization markers were observed following the conditional deletion of ferroportin from the myeloid lineage ([@bib58]). More recently, and in accordance with our findings, the knock down of glia maturation factor-γ (GMFG) in macrophages was shown to cause an iron-deficiency response and M2 macrophage polarization associated with reduced mitochondrial respiration chain components, ISCU, and basal oxygen consumption and an increased HIF response ([@bib1]). Likewise, treatment with iron led to M1 polarization in mice BMDMs ([@bib26]).

The acute iron chelation in experimental glomerulonephritis resulted in *de novo* lipid synthesis but ameliorated the renal outcome. Considering that defective fatty acid oxidation was linked to fibrosis in CKD ([@bib32]), these results argue in favor of a possible transient beneficial role of *de novo* lipogenesis in inflammation, as observed by others ([@bib54], [@bib65]). The systemic use of DEF in macrophage-dependent inflammatory disease should take into account the extent of iron loading in macrophages residing in different tissues. In fact, depending on tissue-dependent variation in ferroportin levels ([@bib16]), the macrophage iron content is likely to differ in different organs, and systemic iron deprivation may not have the same effect on infiltrating and tissue-resident macrophages.

When compared with the well-known LPS/Toll-like receptor 4 (TLR4)-induced Warburg effect in macrophages, iron deprivation-mediated immunometabolism could be considered atypical (i.e., a sterile Warburg effect devoid of pro-inflammatory programming), suggesting the different degrees of this phenomenon in the spectrum model of macrophage plasticity. In summary, immunometabolic changes derived from acute iron deprivation in macrophages could be considered a future therapeutic angle in macrophage-dependent inflammatory disease.

STAR★Methods {#sec4}
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Key Resources Table {#sec4.1}
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REAGENT or RESOURCESOURCEIDENTIFIER**Antibodies**ATF-4 (D4B8) Rabbit mAbCell Signaling TechnologiesCat\# 11815Anti-SDHBAbcamCat\# ab14714Anti- ACTBSanta CruzCat\# sc-47778Anti-rat ED1Bio-RadCat\# MCA341Ranti-PCNAAbcamCat\# ab29Polyclonal Rabbit Anti-mouse immunoglobulins/HRPDAKOCat\# P0260Polyclonal Swine Anti-rabbit immunoglobulins/HRPDAKOCat\# P0217**Chemicals, Peptides, and Recombinant Proteins**Recombinant Human M-CSFPeproTechCat\# AF-300-25Oil-Red-OSigmaCat\# O0625HaematoxylinSigmaCat\# MHS16Iron(III) chloride (FeCl~3~)SigmaCat\# 451649Deferiprone (DEF)SigmaCat\# 3794092-deoxyglucose (2-DG)SigmaCat\# D6134NADPSigmaCat\# N5755cis-aconitic acidSigmaCat\# A3412MTTSigmaCat\# M5655phenazine methosulfateSigmaCat\# P9625isocitrate dehydrogenaseSigmaCat\# I5036CeruleninSigmaCat\# C2389**Critical Commercial Assays**Seahorse XF Cell Mito Stress Test KitAgilent TechnologiesCat \#103015-100RNeasy mini kitQIAGENCat\# 74106RNase-free DNase KitQIAGENCat\# 79254NEBNext Ultra II Directional RNA Library Prep kitNEBCat\# E7760iScript cDNA Synthesis KitBio-RadCat\# 170-8891Brilliant II SYBR Green QPCR Master MixAgilentCat\# 600828Pierce BCA Protein Assay KitThermo Fisher ScientificCat\# 23225IL-1β ELISAInvitrogenCat\# 88-7261-88TNFα ELISAInvitrogenCat\# 88-7346-88**Deposited Data**RNA-sequencing dataThis paperGEO accession number [GSE128885](ncbi-geo:GSE128885){#intref0010}**Oligonucleotides**[Table S2](#mmc1){ref-type="supplementary-material"}This paperN/A**Software and Algorithms**picard (v.2.6.0)N/A<https://broadinstitute.github.io/picard/>edgeR (v.3.22.3)([@bib59])<https://bioconductor.org/packages/release/bioc/html/edgeR.html>DESeq2 (v.1.14.1)([@bib41])<https://bioconductor.org/packages/release/bioc/html/DESeq2.html>pcaExplorer (v.2.6.0)N/A<https://github.com/federicomarini/pcaExplorer>pheatmap (v 1.0.10)N/A<https://cran.r-project.org/web/packages/pheatmap/index.html>ggplot2 (v.3.0.0)([@bib81])<https://cran.r-project.org/web/packages/ggplot2/index.html>R/Bioconductor environment (v.3.4.4)N/A<http://www.R-project.org/>Gene Set Enrichment Analysis (GSEA) (v5.2)([@bib66])<http://software.broadinstitute.org/gsea/index.jsp>STRING database([@bib69])<https://string-db.org/>GraphPad prism (v 7.02)GraphPad SoftwareN/A**Other**RPMI 1640 mediumLife TechnologiesCat\# 11879020Fetal calf serum (FCS)Labtech InternationalCat\# FB-1001Hanks' Balanced Salt Solution (HBSS)Life TechnologiesCat\# 14170112HistopaqueSigmaCat\# 1077Seahorse XF RPMI mediumAgilent TechnologiesCat \# 103576-100SILAC mediumSILAC mediumCat\# A2494201L-glutamineThermo Fisher ScientificCat\# 25030081L-ArginineSigmaCat\# A8094L-LysineSigmaCat\# L8662D-Glucose U-13C, 99%Cambridge isotope laboratoriesCat\# CLM-1396AMPure XP BeadsBeckman CoulterCat\# A63880SuperSignal West Femto Chemiluminescent SubstrateThermo Fisher ScientificCat\# 34580TWEEN 20SigmaCat\# P1379ON-TARGETplus SMARTpool - HumanDharmaconCat\# L-HUMAN-XXDharmaFECT 1 Transfection ReagentDharmaconCat\# T-2001OPTIMEMThermo Fisher ScientificCat\# 11058021

Lead Contact and Materials Availability {#sec4.2}
---------------------------------------

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Jacques Behmoaras (<Jacques.behmoaras@imperial.ac.uk>).

Experimental Model and Subject Details {#sec4.3}
--------------------------------------

### Rats {#sec4.3.1}

WKY (male, 16-weeks old, WKY/NCrl) rats used for NTN experiments were purchased from Charles River UK. All rats were used straight from the source by housing them until the appropriate experimental age. All procedures were performed in accordance to institutional guidelines and procedures approved by the UK Home Office (United Kingdom Animals Scientific Procedures Act, 1986).

### CKD patients {#sec4.3.2}

Acute effects of intravenous iron administration were investigated in patients with stable non-immune chronic kidney disease, not requiring renal replacement therapy. Samples were provided after written informed consent, and in accordance with NHS Health Research authority approval. A summary of patient characteristics is provided in [Table S1](#mmc1){ref-type="supplementary-material"}. All patients were clinically well, without evidence of acute infection or incurrent illness at the time of iron administration, and none had received intravenous iron or blood transfusion in the preceding three months.

Method Details {#sec4.4}
--------------

### Isolation of macrophages and PBMCs {#sec4.4.1}

Human monocyte-derived macrophages (hMDMs) were differentiated from buffy cones from healthy donors using gradient separation (Histopaque 1077, Sigma) and adhesion purification. Following Histopaque separation, peripheral blood mononuclear cells were re-suspended in RPMI 1640 (Life Technologies), and monocytes were purified by adherence for 1 hour at 37°C, 5% CO~2~. The monolayer was washed three times with HBSS to remove non-adherent cells, and monocytes were matured for 5 days in RPMI containing 100 ng/mL macrophage colony-stimulating factor (M-CSF, PeproTech, London, UK) and 10% fetal calf serum (Labtech International). For the deferiprone (DEF) treatment, macrophages were treated with 500 μM DEF (Sigma), in full culture media overnight. Cells were then prepared for either RNA-sequencing or LC-MS experiments using D-Glucose U-^13^C. For rescue experiments involving the addition of FeCl~3~, macrophages deprived from iron with over-night DEF treatment, were treated with FeCl~3~ (200 μM, Sigma) for 8 hours, after which the cells were isolated and used in different assays. Lipopolysaccharide (LPS, Sigma) treatment of hMDMs was used either for RNA-seq or LC-MS experiments.

CKD patients received intravenous iron, as Ferinject (ferric carboxymaltose, 50mg/mL) at a total dose of 1-1.5g by slow infusion over 30 minutes. Peripheral blood was drawn in EDTA immediately prior and 120 min following iron infusion, and processed immediately. Peripheral blood mononuclear cells (PBMCs) were isolated by Histopaque (1077, Sigma) density gradient centrifugation and used for ATF4 Western Blotting before and after iron infusion.

### Metabolic extracellular flux analysis {#sec4.4.2}

Real-time measurements of OCR and ECAR were performed using a Seahorse XF96 Extracellular Flux Analyzer (Agilent Technologies). hMDMs cultured for 5 days in presence of RPMI containing M-CSF (100 ng/ml) and FCS (10%) were washed and incubated with DEF. Cells were then washed, re-suspended using the non-enzymatic cell dissociation buffer (Sigma) and 5 × 10^5^ hMDMs were seeded as a monolayer in a 96-well microplate containing Seahorse XF RPMI medium (Agilent Technologies). The different metabolic drugs were injected (oligomycin 1μM, FCCP 2μM, rotenone/antimycin 1μM, 2-DG 50mM) during real-time measurements of OCR and ECAR, using the Seahorse XF Cell Mito Stress Test Kit (Agilent Technologies). Basal respiration was calculated as the last measurement before addition of oligomycin -- non mitochondrial respiration (minimum rate measurement after Rot/AntA). Maximal respiration is shown as the maximum rate measurement after addition of FCCP -- non mitochondrial respiration. Estimated ATP production designates the last measurement before addition of oligomycin -- minimum rate after oligomycin. Glycolysis refers to ECAR values before the addition of oligomycin.

### Stable isotope tracing by liquid chromatography-mass spectrometry (LC-MS) {#sec4.4.3}

For stable isotope tracing, human macrophages (treated or left as basal) were incubated for 8 hours with SILAC medium lacking glucose and phenol red (GIBCO) with addition of L-glutamine (0.5 mM), arginine (200 mg/L), lysine (40 mg/L) and uniformly labeled glucose (2 g/L D-Glucose U-^13^C, 99%, Cambridge isotope laboratories). Cells were then washed three times with PBS and 200μl of extraction buffer (50% LC-MS grade methanol and 30% acetonitrile, 20% ultrapure water) was added per 10^6^ cells. Following 15 min incubation in dry ice, the cells were scraped off and kept under vigorous shaking for 15 min at 4°C, and left for 1 hour incubation at −20°C. Following centrifugation, the supernatant was stored at −80°C until further analysis. For the cell supernatant analysis, the same procedure was performed in supernatant obtained from 10^6^ cells. For the steady-state metabolomics analysis, cells were stimulated with LPS and DEF or left unstimulated (basal) at indicated times, followed by the same extraction procedure described above.

Samples were randomized in order to avoid bias due to machine drift and processed blindly. LC-MS analysis was performed using a Q Exactive mass spectrometer (Thermo Fisher Scientific) coupled to a Dionex U3000 UHPLC system. The liquid chromatography system was fitted with a Sequant ZIC-pHILIC column (150 mm × 2.1 mm) and guard column (20 mm × 2.1 mm) from Merck Millipore (Germany) and temperature maintained at 40°C. The mobile phase was composed of 20 mM ammonium carbonate and 0.1% ammonium hydroxide in water (solvent A), and acetonitrile (solvent B). The flow rate was set at 200 μL/min with the gradient as described previously ([@bib42]). The mass spectrometer was operated in full MS and polarity switching mode. The acquired spectra were analyzed using XCalibur Qual Browser and XCalibur Quan Browser software (Thermo Fisher Scientific). To generate the heatmap, the raw data were normalized by total ion count and missing values were replaced by half of the minimum value of each metabolite. Heatmap was then generated with the heatmap.2 function of the gplots package by creating z-score values and using default clustering methods.

### RNA extraction and library preparation {#sec4.4.4}

Total RNA was extracted from hMDMs using Trizol (Invitrogen) and RNeasy mini kit (QIAGEN) according to manufacturer's instructions, with an additional purification step by on-column DNase treatment using the RNase-free DNase Kit (QIAGEN) to ensure elimination of any genomic DNA. The integrity and quantity of total RNA was determined using a NanoDrop 1000 spectrophotometer (Thermo Fisher Scientific) and Agilent 2100 Bioanalyzer (Agilent Technologies). 500 ng of total RNA was used to generate RNA-seq libraries using NEBNext Ultra II Directional RNA Library Prep kit from Illumina, according to the manufacturer's instructions. Briefly, RNA was purified and fragmented with poly-T oligo-attached magnetic beads, using two rounds of purification followed by the first and second cDNA strand synthesis. Next, cDNA 3′ ends were adenylated and adapters ligated followed by 11 cycles of library amplification. The libraries were size selected using AMPure XP Beads (Beckman Coulter), subsequently purified and their quality was checked using Agilent 2100 Bioanalyzer. Samples were randomized to avoid batch effects and multiplexed libraries were run on a single lane (8 samples/lane) of the HiSeq 2500 platform (Illumina) to generate 100bp paired-end reads.

### Bioinformatics {#sec4.4.5}

An average depth of 52 M reads per sample was achieved. Sequencing adapters were removed using Trimmomatic (v.0.36) and the reads quality was checked using FastQC (v.0.11.2) before and after trimming. Reads were aligned to the human genome (GRCh38.primary_assembly.genome.fa; annotation: gencode.v25.annotation.gtf) using tophat2 package (v.2.1.0: -b2-sensitive,--library-type fr-firststrand). An average mapping percentage of 97.1% was achieved and the average number of properly paired reads was 51.4 M (∼95%). Mapping quality, read distribution, gene body coverage, GC content and rRNA contamination, were checked using picard (v.2.6.0) software. Gene level read counts were computed using HT-Seq-count (v.0.6.1) with strict "-m intersection-strict" mode. Genes with less than 10 aligned reads across all samples were filtered out as lowly expressed genes, resulting in 15,732 expressed genes. Differential gene expression analysis between groups was performed using DESeq2 (v.1.14.1) and significantly differentially expressed genes were reported using a cut-of fold-change (FC) at 1.5 and below 1% Benjamini-Hochberg (BH) adjusted *P*-value (*P*~adj~). Unsupervised hierarchical clustering and principal component analysis (PCA) were performed using pcaExplorer (v.2.6.0, <https://github.com/federicomarini/pcaExplorer>) and pheatmap (v 1.0.10, <https://cran.r-project.org/web/packages/pheatmap/index.html>) packages respectively. Volcano plots of differentially expressed genes were generated using ggplot2 (v.3.0.0, <https://cran.r-project.org/web/packages/ggplot2/index.html>) package. All raw RNA-seq data processing steps were performed in Cx1 high-performance cluster computing environment, Imperial College London. Further analyses were conducted in R/Bioconductor environment v.3.4.4 (<http://www.R-project.org/>).

Gene Set Enrichment Analysis (GSEA v5.2, <http://software.broadinstitute.org/gsea/index.jsp>) was utilized to identify potential specific biological pathway or signature enrichment between different treatment groups. All gene sets with an FDR less than 0.25 were considered as statistically significant. For gene ontology (GO) analysis, a cut-of (FC \> 1.5, P~adj~ \< 0.01) was applied to the differentially expressed genes and the resulting transcripts were entered to STRING database (<https://string-db.org/>) to interrogate protein-protein interactions together with pathway enrichement.

### Quantitative RT-PCR {#sec4.4.6}

Total RNA was extracted from human macrophages using the TRIzol reagent (Invitrogen) according to the manufacturer's instructions, and cDNA was synthesized using iScript cDNA Synthesis Kit (Bio-Rad). A total of 10 ng cDNA for each sample was used. All quantitative RT-PCRs were performed on a ViaA 7 Real-Time PCR System (Life Technologies) using Brilliant II SYBR Green QPCR Master Mix (Agilent), followed by ViiA 7 RUO Software for the determination of Ct values. Results were analyzed using the comparative Ct method, and each sample was normalized to the reference mRNA level of *HPRT* gene, to account for any potential cDNA loading differences.

### Western blotting {#sec4.4.7}

Human macrophages were lysed in Laemmli sample buffer supplemented with protease inhibitors and resolved by SDS-PAGE, transferred into PVDF membranes, and subjected to immunoblotting with the primary antibodies against ATF4 (Cell Signaling Technologies), SDHB (Abcam), ACTB (Santa Cruz) and secondary detection antibodies. The probed proteins were detected using SuperSignal West Femto Chemiluminescent Substrate (Thermo Fisher Scientific Inc., Rockford, IL).

### RNA interference {#sec4.4.8}

hMDMs were re-plated in six-well plates (1 × 10^6^ cells per well) in RPMI (Invitrogen) overnight and transfected with siGENOME SMARTpool for human *ISCU* (100 nM, Dharmacon SMART pool) or non-targeting siRNA pool as the scrambled control siRNA using Dharmafect 1 (1:50, Dharmacon) as a transfection reagent in OPTIMEM medium (Invitrogen). Following 8 h incubation with OPTIMEM media containing either *ISCU* or non-targeting siRNA, cells were washed and further cultured for 48 h in presence of RPMI media containing M-CSF and FCS. Iron supplementation was achieved by culturing the macrophages for an additional 8 hours in presence of FeCl~3~.

### ELISA {#sec4.4.9}

Detection of human IL-1β and TNFα (Invitrogen) in hMDM culture supernatants at indicated conditions, were performed by sandwich ELISA, using technical duplicates, following the manufacturer's recommendations. Light absorbance was measured using Multiscan Ascent (Thernofisher).

### Nephrotoxic Nephritis and immunohistochemistry {#sec4.4.10}

Male WKY rats (Charles River UK) weighing 300-360 g were used for the induction of nephrotoxic nephritis (NTN). Nephrotoxic serum was prepared in rabbits and NTN was induced by intravenous injection as previously described ([@bib70]). Groups of animals were given either DEF (200 mg/kg/day in 0.1% carboxymethyl cellulose by oral gavage) or vehicle only. Rats were individually housed in metabolic cages overnight for urine collection, and urinary protein levels were determined by sulphosalicylic acid method. Serum blood urea nitrogen and creatinine were measured using an Abbott Architect c8000 clinical chemistry analyzer. Paraffin-embedded kidneys were sectioned for periodic acid-Schiff (PAS) staining. Fibrin deposition was scored as the number of glomerular quadrants involved from '0' (absence of fibrin) to '4+' (fibrin occupying more than ¾ of the glomerulus) in 50 consecutive glomeruli. Crescent formation was recorded as presence/absence in 100 consecutive glomeruli and presented as percentage of glomeruli with crescents. Immunohistochemistry was performed and developed with EnVision+ System-HRP (Dako) using mouse anti-rat ED1 (Bio-Rad) and anti-PCNA \[PC10\] (Abcam) antibodies. Pictures of 20 consecutive glomeruli from each ED1 stained slide were taken with a QImaging Retiga 2000R Scientific CCD Camera, using Image-Pro® Plus Version 7.0 software. The size of the glomeruli and ED1 stained area in glomeruli were measured using ImageJ software. The number of anti-PCNA stained cells in 20 consecutive glomeruli were counted. All histological and immunohistochemical analyses were performed in a blinded manner.

### Oil-red-o staining {#sec4.4.11}

Optimal Cutting Temperature compound embedded frozen rat kidneys were sectioned at 5 microns thickness and 10% formalin fixed for 10 min at room temperature prior to staining. hMDMs cultured in slide-chambers were treated with DEF alone (500 μM) or together with FeCl~3~ (200 μM) or cerulenin (20 μM) for 48 hours. The cells were fixed with 10% formalin at 4°C. Kidney sections and hMDMs were stained for lipids by Oil-Red-O (0.5% Oil red O dye in 60% isopropanol; Sigma) and counterstained with Haematoxylin (Sigma). Pictures were obtained by light microscopy using a Leica DM6 B upright microscope and a Leica DFC7000 T camera.

### Aconitase in-gel assay {#sec4.4.12}

In-gel aconitase activities were measured as described previously ([@bib29], [@bib73]). Aconitase activity gels are composed of a separating gel containing 8% acrylamide (132 mM Tris base, 132 mM borate, 3.6mM citrate) and a 4% acrylamide (67 mM Tris base, 67 mM borate, 3.6 mM citrate) stacking gel. The running buffer contains 25 mM Tris pH 8.3, 192 mM glycine, and 3.6 mM citrate. Protein concentration of macrophage lysates was measured by using the Pierce BCA Protein Assay Kit and the sample buffer contained 25 mM Tris-Cl, pH 8.0, 10% glycerol, and 0.025% bromophenol blue. Electrophoresis was carried out at 180 V, 4°C, for 2 hours. Aconitase activities were assayed by incubating the gel in the dark at 37°C in 100 mM Tris (pH 8.0), 1 mM NADP, 2.5 mM cis-aconitic acid, 5 mM MgCl~2~, 1.2 mM MTT, 0.3 mM phenazine methosulfate, and 5 U/ml isocitrate dehydrogenase (Sigma).

Quantification and Statistical Analysis {#sec4.5}
---------------------------------------

Data are presented as mean ± s.e.m. and analyzed using GraphPad Prism software (version 7.02; GraphPad). One-way ANOVA (followed by Dunnett' or Tukey's multiple comparison tests) and Student's t test were performed unless otherwise stated. Differences in percentage of fold change following *ISCU* siRNA knockdown were tested for significance using a one-sample-t test. In uniformly labeled \[U\]-13C-glucose experiments, one-way ANOVA was applied to test for significance in glucose-derived isotopologues.

Data and Code Availability {#sec4.6}
--------------------------

The accession number for the RNA-sequencing data reported in this paper is GEO accession number GEO: [GSE128885](ncbi-geo:GSE128885){#interref0100}.
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